maternal phenylketonuria
Metabolic · 2020–2020
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| sapropterin Treatment of hyperphenylalaninaemia (HPA) due to phenylketonuria (PKU) in pregnant women or those actively planning to become pregnant, in combination with a… | Dec 2020 | Deferred | 35 individuals Rare Voices Australia · Metabolic Dietary Disorders Association |
Who spoke
Rare Voices Australia · Metabolic Dietary Disorders Association
What the PBS pays
$17M in government benefit over 2024–25, across 2,436 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| sapropterin | $17.3M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.